Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOY-305-03 Thorough QT Study in Healthy Adults
jRCT2071200109Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of camostat mesilate in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Prolongation of QT/QTc interval. Started Apr 2021; status: completed.
02
Drugs
camostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200109.